Related Experiment Video

Updated: May 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians

Patrick Ingiliz1, Jürgen K Rockstroh

  • 1Medical Center for Infectious Diseases, Berlin, Germany. ingiliz@mvz-mib.de

Liver International : Official Journal of the International Association for the Study of the Liver
|April 19, 2012
PubMed

Insights

New hepatitis C (HCV) protease inhibitors offer improved cure rates for HIV-HCV co-infected patients. Careful management of drug interactions with antiretroviral therapy is crucial for successful treatment outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Hepatitis C virus (HCV) infection poses significant health challenges, particularly for patients co-infected with human immunodeficiency virus (HIV).
  • Existing treatments for chronic HCV in HIV-HCV co-infected individuals often yield lower response rates and can be complicated by severe liver disease.
  • The advent of novel HCV protease inhibitors (PI) presents a promising opportunity to enhance treatment efficacy.

Purpose of the Study:

  • To evaluate the potential of new HCV protease inhibitors, telaprevir (TVR) and boceprevir (BOC), in improving cure rates for HIV-HCV co-infected patients.
  • To identify and address the critical challenge of managing drug-drug interactions between HCV PIs and antiretroviral drugs.
  • To provide guidance on optimizing treatment strategies for this vulnerable patient population.

Main Methods:

  • Review of available efficacy data from Phase II clinical trials of TVR and BOC in HIV-HCV co-infected patients.
  • Analysis of pharmacokinetic profiles and known metabolic pathways (cytochrome P450 3A4) to predict potential drug-drug interactions.
  • Assessment of drug interaction data with specific antiretroviral agents, including non-nucleoside reverse transcriptase inhibitors and HIV PIs.

Main Results:

  • TVR and BOC show potential to improve cure rates in HIV-HCV co-infected patients.
  • Significant drug-drug interactions are anticipated between HCV PIs and antiretroviral drugs due to shared metabolic pathways.
  • Specific antiretroviral combinations are identified as potentially safe or contraindicated with TVR and BOC, requiring dose adjustments or avoidance.

Conclusions:

  • The introduction of TVR and BOC offers new therapeutic avenues for achieving HCV cure in HIV-HCV co-infected individuals.
  • Clinical decisions regarding treatment initiation must consider fibrosis stage and prior treatment history.
  • Close monitoring and optimization of HIV therapy are essential to mitigate risks associated with drug-drug interactions.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...